Clinical Trial Detail

NCT ID NCT04150887
Title Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

acute myeloid leukemia

Therapies

ARGX-110 + Azacitidine + Venetoclax

ARGX-110 + Venetoclax

ARGX-110 + Azacitidine

Age Groups: adult senior

No variant requirements are available.